Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













BI 1358894







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

BI 1358894 is an investigational antidepressant that works as a transient receptor potential cation channel inhibitor. It is developed by Boehringer Ingelheim.[1][2][3][4]

References[edit]

  1. ^ Fuertig, René; Goettel, Markus; Herich, Lena; Hoefler, Josef; Wiebe, Sabrina T.; Sharma, Vikas (29 November 2023). "Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies". CNS Drugs. 37 (12): 1081–1097. doi:10.1007/s40263-023-01041-4. PMC 10703969. PMID 38019355.
  • ^ Grimm, Simone; Keicher, Christian; Paret, Christian; Niedtfeld, Inga; Beckmann, Christian; Mennes, Maarten; Just, Stefan; Sharma, Vikas; Fuertig, René; Herich, Lena; Mack, Salome; Thamer, Claus; Schultheis, Christian; Weigand, Anne; Schmahl, Christian; Wunder, Andreas (December 2022). "The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder". European Neuropsychopharmacology. 65: 44–51. doi:10.1016/j.euroneuro.2022.10.009. hdl:2066/286079. PMID 36343427.
  • ^ Goettel, Markus; Fuertig, Rene; Mack, Salome Rebecca; Just, Stefan; Sharma, Vikas; Wunder, Andreas; den Boer, Johan (29 November 2023). "Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males". CNS Drugs. 37 (12): 1099–1109. doi:10.1007/s40263-023-01042-3. PMC 10703963. PMID 38019356.
  • ^ Goettel, Markus; Höfler, Josef; Fuertig, Rene; Sharma, Vikas; Göttel, Markus (May 2020). "First-In-Human Study of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability". Biological Psychiatry. 87 (9): S289–S290. doi:10.1016/j.biopsych.2020.02.747. S2CID 218537025.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=BI_1358894&oldid=1199045778"
    Categories: 
    ●Ion channel blockers
     ●Drugs developed by Boehringer Ingelheim
     ●Experimental antidepressants
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Orphaned articles from December 2023
     ●All orphaned articles
      


    ●This page was last edited on 25 January 2024, at 19:32 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki